Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Terbinafine · 1 trial · 1 indication
pharmacokinetics
pharmacokinetics
| Arm | Type | Description |
|---|---|---|
| A(test)/B(reference) | EXPERIMENTAL | Initial administration of test and crossover to reference |
| B(reference)/A(test) | EXPERIMENTAL | Initial administration of reference and crossover to test |
| Name | Type | Description |
|---|---|---|
| Terbinafine 250 mg | DRUG | Test product |
Inclusion Criteria: Inclusion Criteria: Males 18-50 years. Healthy based on comprehensive medical history, lab tests, Chest x-ray, Electrocardiogram, negative tests for Hepatitis B and C, and HIV. Negative urine doping test. BMI 19-26.5 kg/m2. Lab test in normal range +/- 10%. Blood pressure 139-90...
Terbinafine is a small molecule drug used for the treatment of mycoses, which are fungal infections. It is being developed by GSK plc. The drug is currently in Phase 1 clinical development, meaning it is investigational and has not yet been approved for use.
Terbinafine is being developed by GSK plc, a biopharmaceutical company listed on the stock exchange under the ticker GSK. The drug is in Phase 1 clinical development for the treatment of mycoses, a type of fungal infection.
Terbinafine is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of mycoses. The drug has not yet been approved by regulatory authorities, and further clinical trials are needed to evaluate its safety and efficacy.
Terbinafine has been studied in a Phase 1 clinical trial with the identifier NCT01772212. This trial was a bioequivalence study for Terbinafine 250 mg, which enrolled 30 participants with mycoses. The trial was completed and included healthy volunteers.
Terbinafine is a drug being developed by GSK plc for the treatment of mycoses. It is a small molecule that is currently in Phase 1 clinical development. No alternative names for this drug have been disclosed.